NCT06236672View on ClinicalTrials.gov

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

CompletedOBSERVATIONAL
Enrollment

348

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

November 29, 2023

Study Completion Date

November 29, 2023

Conditions
Type 2 DiabetesChronic Kidney Diseases
Interventions
DRUG

GLP-1 receptor agonist

GLP-1 RA initiated between January 2019 and December 2022

DRUG

basal insulin

basal insulin initiated between January 2019 and December 2022

Trial Locations (1)

M4G 3E8

LMC Diabetes & Endocrinology Ltd., Toronto

All Listed Sponsors
collaborator

Novo Nordisk Canada Inc.

UNKNOWN

lead

LMC Diabetes & Endocrinology Ltd.

OTHER